公司代码：688247 公司简称：宣泰医药 上海宣泰医药科技股份有限公司 2025 年半年度报告 1 / 189 上海宣泰医药科技股份有限公司2025 年半年度报告 上海宣泰医药科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司主营业务、核心竞争力不存在重大不利变化，持续经营能力不存在重大风险。公司已在 本报告"第三节管理层讨论与分析"-"四、风险因素"中详细披露了生产经营过程中可能面临的 各种风险，提请投资者查阅。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人郭明洁、主管会计工作负责人吴一鸣及会计机构负责人（会计主管人员）卫培 华声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经公司第二届董事会第十八次会议决议，公司 2025 年半年度拟以实施权益分派股权登记日登 记的总股本扣减公司回购专用证券账户中股份为基数分配利润，本次利润分 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-034 上海宣泰医药科技股份有限公司 关于 2025 年半年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、利润分配方案内容 公司拟向全体股东每 10 股派发现金红利 0.25 元（含税）。根据《上海证券 交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，上市公司回购 每股分配比例：每股派发现金红利 0.025 元（含税）。不进行资本公积金 转增股本，不送红股。 因上海宣泰医药科技股份有限公司（以下简称"公司"）实施股份回购 事项，根据相关规定，公司通过回购专用证券账户持有的本公司股份不 参与本次利润分配。本次利润分配以实施权益分派股权登记日的总股本 扣减公司回购专用证券账户中股份为基数，具体日期将在权益分派实施 公告中明确。 如在实施权益分派的股权登记日前公司总股本扣减公司回购专用证券 账户中的股份数量发生变动的，公司拟维持每股分配比例不变，调整拟 分配的利润总额，并将在权益分派实施公告中明确具体调整情况 ...

宣泰医药公告，2025年上半年营业收入2.2亿元，同比增长0.74%。净利润4558.57万元，同比下降 15.82%。公司拟向全体股东每10股派发现金红利0.25元（含税），拟派发现金红利合计1122.51万元 （含税），占2025年1-6月归属于母公司股东的净利润比例为24.62%。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688247 证券简称：宣泰医药 公告编号：2025-031 上海宣泰医药科技股份有限公司 关于控股股东自愿承诺不减持公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 上海宣泰医药科技股份有限公司（以下简称"公司"）于2025年8月15日收到公司控股股东上海联和投资 有限公司（以下简称"联和投资"）出具的《关于自愿承诺未来24个月不减持上海宣泰医药科技股份有限 公司股份的承诺函》。现将相关情况公告如下： 基于对公司未来发展前景的信心和对公司长期价值的认可，同时为增强广大投资者信心，切实维护投资 者权益和资本市场稳定，公司控股股东联和投资自愿承诺，自2025年8月25日起24个月内（2025年8月25 日至2027年8月24日）不通过集中竞价交易、大宗交易等方式减持其所持有的公司股份。在上述承诺期 间，如发生资本公积转增股本、派送股票红利、配股等产生新增股份，亦遵守该不减持承诺。 截至本公告披露日，公司控股股东联和投资持股情况如下： ■ 公司董事会将对 ...

Mergers and Acquisitions - Huahong Company is planning to acquire controlling stakes in Shanghai Huali Microelectronics through a combination of issuing shares and cash payments to resolve competition issues related to its IPO [1] Performance Disclosure - Guangku Technology reported a revenue of 597 million yuan for the first half of 2025, representing a year-on-year increase of 41.58%, with a net profit attributable to shareholders of 51.87 million yuan, up 70.96% [2] - Huayou Cobalt disclosed a revenue of 37.2 billion yuan for the first half of 2025, showing a year-on-year growth of 23.78%, with a net profit of 2.711 billion yuan, an increase of 62.26% [3] - Guangli Micro reported a revenue of 246 million yuan for the first half of 2025, reflecting a year-on-year increase of 43.17%, with a net profit of 15.6842 million yuan, up 518.42% [4] Shareholding Changes - Nanwei Medical announced that its shareholder Zhongke Investment plans to reduce its stake by up to 2%, equating to a maximum of 3.7569 million shares [5] - Shandong Zhanggu reported that shareholders Niu Yusheng and Fang Shupeng completed their plan to reduce their holdings by approximately 700,000 shares, representing 0.225% of the total share capital [6] - Xuantai Pharmaceutical's controlling shareholder voluntarily committed not to reduce its stake for 24 months starting from August 25, 2025, to enhance investor confidence [7] Risk Matters - Guotai Environmental announced that its controlling shareholder and chairman Chen Baixiao has been placed under detention and is under investigation [8] - *ST Xinchao reported that a lawsuit has been adjudicated, and the company expressed regret for not disclosing relevant information during a management transition [9] - Shandong Zhanggu stated that there have been no significant changes in its operational situation or external environment despite a recent stock price fluctuation exceeding 20% [10]

Core Viewpoint - The controlling shareholder of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. has voluntarily committed not to reduce its shareholding in the company for the next 24 months, aiming to enhance investor confidence and maintain market stability [1][2]. Shareholder Commitment - The controlling shareholder, Shanghai Lianhe Investment Co., Ltd., has issued a commitment letter stating that from August 25, 2025, to August 24, 2027, it will not reduce its shareholding through various trading methods [1]. - This commitment includes adherence to the non-reduction promise in the event of capital reserve conversion into share capital, stock dividends, or rights issues that generate new shares [1]. Shareholding Status - As of the announcement date, the shareholding status of the controlling shareholder is detailed, although specific numbers and percentages are not provided in the text [1].

证券代码：688247 证券简称：宣泰医药 公告编号：2025-032 上海宣泰医药科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 本次股票上市流通总数为311,018,400股。 ? 本次股票上市流通日期为2025 年 8 月 25 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会《关于同意上海宣泰医药科技股份有限公司首 次公开发行股票注册的批复》 三、本次上市流通的限售股的有关承诺 根据《上海宣泰医药科技股份有限公司首次公开发行股票并在科创板上市招 股说明书》及《上海宣泰医药科技股份有限公司关于控股股东自愿承诺不减持公 司股份的公告》，本次申请解除股份限售的股东关于其持有的限售股的有关承诺如 下： （一） 关于限售安排、自愿锁定及延长锁定期限承诺 （证监许可[2022]1383 号），上海宣泰医药科技股份有 限公司（以下简称"公司"、 "宣泰医药"）获准向社会公开发行人民币普通股（A） 股 45,340, ...

Group 1 - The controlling shareholder, Shanghai Lianhe Investment Co., Ltd., has committed not to reduce its shareholding in Xuantai Pharmaceutical for 24 months starting from August 25, 2025, to enhance investor confidence and stabilize the capital market [1] - On August 25, 2023, a total of 311 million shares of Xuantai Pharmaceutical will be unlocked, accounting for 68.61% of the total share capital, with Lianhe Investment holding 233 million shares, representing 75% of the unlocked shares [1] - The commitment from the controlling shareholder significantly reduces the potential share reduction to 7.8 million shares, alleviating market liquidity pressure [1] Group 2 - Xuantai Pharmaceutical focuses on high-end generic drugs and has developed a leading drug chemical formulation platform in China, with a strong emphasis on R&D and technological innovation [2] - The company has established differentiated technological barriers in areas such as "insoluble drug solubilization technology" and "controlled-release technology," facilitating the transition from price competition to high value-added development [2] - As of the end of 2024, Xuantai Pharmaceutical is expected to have 16 approved products, including several first-generic products domestically and internationally, with products already exported to multiple countries [2] Group 3 - Since its listing in 2022, Xuantai Pharmaceutical has maintained a shareholder-centric approach, optimizing management and governance, and has distributed a total cash dividend of 74.36 million yuan over three years [3] - The company completed a share buyback in February 2025, repurchasing 4.3361 million shares, which is 0.96% of the total share capital, at a cost of 36.126 million yuan [3] - Xuantai Pharmaceutical plans to continue its dual-driven strategy of innovation and international expansion to accelerate product commercialization and deliver stable returns to investors [3]

Core Viewpoint - The controlling shareholder of Xuantai Pharmaceutical, Shanghai Lianhe Investment Co., Ltd., has voluntarily committed not to reduce its shareholding in the company for 24 months starting from August 25, 2025, to enhance investor confidence and maintain market stability [1][2]. Group 1: Shareholder Commitment - The commitment from the controlling shareholder comes at a critical time when the company's original shareholders' restricted shares are about to be unlocked, alleviating market concerns about large-scale share reductions [2]. - On August 25, 2023, a total of 311 million shares will be unlocked, accounting for 68.61% of the total share capital, with Lianhe Investment holding 233 million shares, representing 75% of the unlocked shares [2]. - The actual reducible shares will be significantly reduced to 7.8 million shares, effectively easing potential liquidity pressure from the concentrated unlocking [2]. Group 2: Business Strengths - Xuantai Pharmaceutical's long-term outlook is supported by its robust core strategic business and the competitive barriers of its high-end formulation technology [3]. - The company focuses on high-end generic drugs and has developed a leading drug chemical formulation platform in China, with a strong emphasis on R&D and technological innovation [3]. - The product portfolio includes 16 approved products by the end of 2024, with several being first generics in both domestic and international markets [3]. Group 3: CRO/CMO Performance - In the CRO/CMO sector, Xuantai Pharmaceutical has successfully assisted in the approval and commercialization of multiple innovative drugs, with over 100 projects completed for global clients [4]. - The company has established partnerships with several well-known pharmaceutical companies, enhancing its market presence and service capabilities [4]. Group 4: Shareholder Returns - Xuantai Pharmaceutical has consistently prioritized shareholder returns, implementing a stable and continuous dividend policy, with a total cash dividend of 74.36 million yuan since its listing in 2022 [5][6]. - The company completed a share buyback in February 2025, repurchasing 4.3361 million shares, which represents 0.96% of the total share capital, further demonstrating its commitment to enhancing shareholder value [6]. - The controlling shareholder's commitment not to reduce holdings is seen as a strong vote of confidence in the company's long-term strategy and management team, reinforcing the company's positive image in the capital market [6].

公告显示，基于对公司未来发展前景的信心和对公司长期价值的认可，同时为增强广大投资者信心，切 实维护投资者权益和资本市场稳定，公司控股股东联和投资自愿承诺，自8月25日起24个月内不通过集 中竞价交易、大宗交易等方式减持其所持有的公司股份。 北京商报讯(记者丁宁)8月17日晚间，宣泰医药(688247)发布公告称，公司于8月15日收到公司控股股东 上海联和投资有限公司(以下简称"联和投资")出具的《关于自愿承诺未来24个月不减持上海宣泰医药科 技股份有限公司股份的承诺函》。 ...